Prenetics Global Limited (NASDAQ:PRE - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Prenetics Global in a report released on Friday, June 13th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($1.01) for the year. The consensus estimate for Prenetics Global's current full-year earnings is ($3.30) per share.
Prenetics Global Stock Down 12.6%
Prenetics Global stock opened at $7.01 on Monday. Prenetics Global has a twelve month low of $3.09 and a twelve month high of $11.99. The company has a 50 day moving average of $6.32 and a 200-day moving average of $5.53. The stock has a market capitalization of $85.56 million, a PE ratio of -1.76 and a beta of 0.17.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings data on Thursday, June 12th. The company reported ($0.80) earnings per share (EPS) for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. The firm had revenue of $17.31 million for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new stake in shares of Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned about 0.10% of Prenetics Global as of its most recent filing with the Securities and Exchange Commission (SEC). 25.01% of the stock is currently owned by institutional investors and hedge funds.
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
